Status:
RECRUITING
Dopamine and Sensorimotor Function in Stuttering
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
National Institute on Deafness and Other Communication Disorders (NIDCD)
University of Washington
Conditions:
Stuttering, Adult
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This study is being done to understand the effect of aripiprazole on adults who stutter. Stuttering is a disorder that affects speech fluency. This study aims to understand sensorimotor pathways of st...
Detailed Description
Stuttering is a disorder of speech fluency that affects 3.5 million people in the USA alone. The goal of this project is to assess whether fluency ehnancement with auditory feedback manipulations or w...
Eligibility Criteria
Inclusion
- native speakers of American English
- for adults who stutter, presence of stuttering will be confirmed, with onset before age 6 years
- Normal hearing
- Ages of 18 to 65 years
- healthy adults without hearing-language difficulties
Exclusion
- self-reported speech-language-hearing difficulties other than stuttering
- self-reported neurological or psychological problems
- other medications (drugs that affect dopaminergic system and/or benzodiazepines)
Key Trial Info
Start Date :
September 30 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT07215884
Start Date
September 30 2025
End Date
June 30 2026
Last Update
October 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Biomagentic Imaging Lab
San Francisco, California, United States, 94143